A donor’s drug profile is one reason for deferral, if there are safety concerns for either donor or recipient.
Historically, cardiac fibrosis has not been a focus for treatment; however, it is now believed that therapy could reduce the progression of heart failure and other cardiovascular diseases.
Adverse effects, primarily cardiovascular in nature, are of concern because of their severe and possibly chronic nature.
Digoxin, a cardiac glycoside, has inotropic effects in addition to effects on cardiac output.
The pathophysiology is not fully understood, rendering pharmacologic treatment difficult.
No true antidote for these agents has been developed, so patients requiring rapid reversal must be appropriately monitored and managed.
Testing for the inflammatory marker CRP may improve risk stratification, especially in intermediate-risk patients.